Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
NEUROLOGICAL SCIENCES(2024)
摘要
ObjectiveTo explore the rate of hypertension incoming in patients treated with monoclonal antibodies against the calcitonin gene-related peptide.BackgroundThe monoclonal antibodies blocking the calcitonin gene-related peptide are unquestionable effective in the prevention of migraine. Despite this, the development of hypertension has been detected in some patients.MethodsThis was a retrospective study conducted at the University Hospital of Modena. Patients were visited quarterly up to 1 year.ResultsGlobally, no significant increase in the blood pressure was detected. The 5.7% of the patients developed a significant increase in their blood pressure. In particular, patients with a pre-existing hypertension were more likely to have a significant increase in the blood pressure.ConclusionThe risk of developing hypertension during a treatment with anti-calcitonin gene-related peptide monoclonal antibodies seems low. Anyway, patients with a pre-existing hypertension should be cautiously monitored because they are more likely to develop hypertension.
更多查看译文
关键词
Migraine,Fremanezumab,Galcanezumab,Erenumab,Blood pressure
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要